金陵药业(000919) - 2017 Q1 - 季度财报

Financial Performance - Revenue for Q1 2017 was ¥831,626,576, a decrease of 4.44% compared to ¥870,225,899 in the same period last year[8] - Net profit attributable to shareholders was ¥43,030,311, down 9.97% from ¥47,796,854 in the previous year[8] - Net profit excluding non-recurring items was ¥40,091,952.98, reflecting a decline of 21.15% from ¥50,846,322.88 year-on-year[8] - The weighted average return on equity decreased to 1.68% from 1.94% in the previous year[8] Cash Flow - Operating cash flow improved significantly, with a net cash flow of -¥5,992,876.55, a 94.63% increase compared to -¥111,570,885.38 in the same period last year[8] - Net cash flow from operating activities increased by 94.63% compared to the same period last year, primarily due to a significant reduction in cash paid for purchasing goods and services[17] - Net cash flow from investing activities decreased by 235.54% year-on-year, as the decline in cash inflows from investment activities was greater than the decline in cash outflows[17] - Net cash flow from financing activities increased by 116.72% compared to the same period last year, mainly due to an increase in cash received from borrowings[17] Assets and Liabilities - Total assets increased by 1.14% to ¥3,901,804,306.79 from ¥3,857,882,074.06 at the end of the previous year[8] - Net assets attributable to shareholders rose by 1.59% to ¥2,579,537,094.46 from ¥2,539,216,117.90 at the end of the previous year[8] - The company's short-term borrowings increased by 44.23% compared to the beginning of the year, mainly due to increased borrowings by a subsidiary[16] - Other receivables rose by 143.07% compared to the beginning of the year, attributed to an increase in receivables from a subsidiary[16] Financial Expenses and Income - Financial expenses increased by 441.15% compared to the same period last year, primarily due to higher interest expenses[16] - The fair value change income increased by 194.81% compared to the same period last year, primarily due to the increase in fair value change income from trading financial assets[17] - Investment income rose by 1866.24% year-on-year, mainly driven by increased securities investment income and dividends from available-for-sale financial assets[17] Investments - The company acquired 12.54% equity in Yizheng Hospital for a total price of ¥28,710,465.09, raising its total ownership to 80.88%[20] - The company reported a total investment in securities amounting to 85,265.1 million yuan, with a year-end holding of 46,319.2 million yuan, resulting in a loss of 1,841.3 million yuan during the reporting period[25] - The company held 20,234.1 million yuan in cash fund investments, representing 24.28% of the total initial holdings[25] - The company’s investment in Huatai Zijin fund was 20,129.6 million yuan, with a reported gain of 64,274.3 million yuan[25] - The company’s stake in Jinfang Technology was 100,000 shares, accounting for 4.03% of the total holdings, resulting in a loss of 2,234.6 million yuan[25] - The company’s investment in FAW Car was 5,419.28 million yuan, with a year-end holding of 470,000 shares, yielding a gain of 107,912 million yuan[25] - The company reported a total of 2,150.58 million yuan in other securities investments at the end of the reporting period[25] - The company’s investment in Hongdu Aviation amounted to 3,196.80 million yuan, with a year-end holding of 150,000 shares, resulting in a gain of 23,700 million yuan[25] - The company’s investment in Pudong Jinqiao was 2,251.90 million yuan, with a loss of 315,900 million yuan during the reporting period[25] - The company’s investment in Southern Asia Dollar Bond Fund was 1,400.00 million yuan, with a gain of 16,644.6 million yuan[25] - The company did not engage in any derivative investments during the reporting period[27]